BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 28836852)

  • 1. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
    Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
    J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
    Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.
    Hu J; Tian J; Zhu S; Sun L; Yu J; Tian H; Dong Q; Luo Q; Jiang N; Niu Y; Shang Z
    Br J Cancer; 2018 Jan; 118(1):88-97. PubMed ID: 29123266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling.
    Lee J; Byun HJ; Lee MS; Jin YJ; Jeoung D; Kim YM; Lee H
    Oncotarget; 2017 Jan; 8(1):1641-1654. PubMed ID: 27926483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
    Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
    Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
    Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer.
    Kolijn K; Verhoef EI; van Leenders GJ
    Oncotarget; 2015 Sep; 6(27):24488-98. PubMed ID: 26041890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells.
    Huaman J; Naidoo M; Zang X; Ogunwobi OO
    Cells; 2019 Jun; 8(6):. PubMed ID: 31226820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
    Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
    J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
    BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
    Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
    Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.